ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 2000 iu / 4 ml - coagulation factor viii

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 500 iu / 4 ml - coagulation factor viii

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - liraglutide - תמיסה להזרקה - liraglutide 6 mg / 1 ml - liraglutide

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - repaglinide - טבליה - repaglinide 0.5 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - repaglinide - טבליה - repaglinide 1 mg - repaglinide - repaglinide - treatment of type ii diabetes .

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - repaglinide - טבליה - repaglinide 2 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.